Welcome to the Stanford Interstitial Lung Diseases Program
The Division of Pulmonary, Allergy, and Critical Care Medicine at Stanford University Medical Center offers a specialty program dedicated to the needs of patients with a variety of Interstitial Lung Diseases (ILDs). Started in 2004, the Stanford Interstitial Lung Disease Clinic cares for patients with a variety of ILDs, including exposure-related occupational and environmental ILDs, autoimmune/connective tissue disease ILDs secondary to Rheumatoid Arthritis, Scleroderma, Dermatomyositis, and Polymyositis, and Idiopathic ILDs such as Idiopathic Pulmonary Fibrosis (IPF), Cryptogenic Organizing Pneumonia, and Sarcoidosis. A large portion of our ILD patients have Idiopathic Pulmonary Fibrosis (IPF) which is scarring of the lung tissue due to unknown (idiopathic) causes. Approximately 250,000 people in the United States and Europe have IPF with approximately 40,000 new cases reported per year in the United States. Our program includes comprehensive care, ground-breaking scientific research, and education and support for people with ILD.
Multidisciplinary Approach for Early Diagnosis: We offer a comprehensive, individualized, multi-disciplinary approach to evaluate patients with possible ILDs who present with symptoms of increasing shortness of breath and cough. Many of our patients have had a difficult and prolonged journey to establish an accurate and early diagnosis. We collaborate closely with our expert colleagues in Rheumatology, Gastroenterology, Pathology, Radiology, Interventional Pulmonology, Thoracic Surgery and Lung Transplantation in order to identify the specific type of ILD and to develop an individualized treatment plan. Patients are reviewed weekly at our Multidisciplinary Interstitial Lung Disease conference to establish a diagnosis and treatment plan based on consensus of this interdisciplinary group of experts.
The interstitial lung disease program at Stanford is comprised of outstanding physicians and staff who are dedicated to improving the lives of patients with interstitial lung diseases through state of the art comprehensive and compassionate clinical care, and cutting edge basic, translational and clinical research aimed at improving outcomes and quality of life for our patients...